CYTR CytRx Corporation

0.33
0  -1%
Previous Close 0.33
Open 0.29
Price To Book 0.6
Market Cap 10,965,825
Shares 33,637,501
Volume 96,806
Short Ratio 1.96
Av. Daily Volume 56,119

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis released November 29, 2016 showed improvement in population with leiomyosarcoma and liposarcoma. Rolling NDA to be filed 4Q 2017.
Aldoxorubicin with doxorubicin
Soft tissue sarcomas refractory cancer
Phase 2 trial completed.
Aldoxorubicin
Cancer - unresectable glioblastoma
Phase 1b dosing initiated February 2018.
Aldoxorubicin
Squamous Cell Carcinoma
Phase 2/3 interim analysis 1H 2020 with data due 1H 2021.
Arimoclomol
sporadic Inclusion Body Myositis (sIBM)
Phase 1b dosing initiated February 2019.
Aldoxorubicin
Refractory colorectal cancer (CRC)
NDA filing due 1H 2020.
Arimoclomol
Niemann-Pick disease Type C (NPC)
Phase 3 top-line data due 1H 2021.
Arimoclomol
Amyotrophic lateral sclerosis (ALS)

Latest News

  1. CytRx Corporation Reports Second Quarter 2019 Financial Results
  2. CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C
  3. CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
  4. CytRx Corporation Discusses Near Term Value from Out-License Deals and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com
  5. CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation
  6. Nasdaq delists shares of FTD, Insys, others
  7. CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C
  8. CytRx Corporation to Commence Trading on OTCQB Venture Market
  9. CytRx: 1Q Earnings Snapshot
  10. CytRx Corporation Reports First Quarter 2019 Financial Results
  11. CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
  12. CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
  13. CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
  14. CytRx Corporation Reports 2018 Financial Results
  15. CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
  16. CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor
  17. CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
  18. CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
  19. CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
  20. CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic